Targeting cd38 with daratumumab plus chemotherapyfor patients with advanced-stage plasmablastoidlarge b-cell lymphoma

HIGHLIGHTS

• who: Yun Kyoung Ryu and colleagues from the Division of Hematology-Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA have published the research: Targeting CD38 with Daratumumab Plus Chemotherapyfor Patients with Advanced-Stage PlasmablastoidLarge B-Cell Lymphoma, in the Journal: (JOURNAL)
• what: The authors report a single-center experience of the treatment of seven patients with advanced-stage LBLC with plasmablastic features using daratumumab in combination with chemotherapy. The authors identified seven patients 2.5plasmablastic years with CD38 and/or expression with daratumumablymphoma in combination with chemotherapy who wefeatures analyzed . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.